Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do you believe reformulation is possible to make B oral?
TIA
I totally agree with what you wrote in that if a BP had offered Leo a proper offer years ago that had a significant increase in royatly percentage as B and K each earned commerciality and grew revenues, thus earning both sides a lot of money and equal risk, that Leo would and should have taken it.
But I believe no BP came forward because the play book always has been the startup bio only gets mere pennies on the dollar at best.
Offers were so meager or lacking that Leo could not take any in good faith to shareholders. Thus we are now at where we are at.
Am I disappointed in the resulting dilution over the years, yes, but they were necessary IMO and Leo did well to keep them below 500MM. What really galled me in your post was saying Leo has been playing the company for his salary and willing to sell out us stockholders for his personal gain. That is the crock of which I spoke.
Now we find ourselves in a position where IPIX has taken ALL THE RISKS and brought Brilacidin to the brink of MASSIVE revenues in the next few years. Thus, I feel IPIX should receive the lion's share of the revenues, not the scraps.
I want Leo to make them pay thru the nose. They were too stupid to realize the value of B, too bad for them, now they pay handsomely to have any part of the platform.
What a crock of crap
How much could it have cost Merck to put out a POS?
And yet some learned clowns were at first praising its properties.
Revolutionary products can do things regular products can't, such as the electric car.
Brilacidin will do the same for medicine IMO
Do you think big auto/big oil would let an engine hit the market that could get 140mpg?
When you talk to anybody regarding IPIX, the first thing they say is how could a company with this great a drug still be only pennies per share (and low pennies at that).
This is what has occurred with what the BP has put into action, the share price stays low, very little new buyers coming in, and cost of capital is extremely high for IPIX. That is why we have gone up more than 300MM shares over the last number of years. They wanted to make sure IPIX couldn't acquire capital at a decent price and that is what has held up the advancement of both K and B as to trials for all these years.
I think what they have been doing is quite apparent and it is working. Same goes for the way this board goes, any good word is immediately slandered and volume comes in to drop the price after any good news.
I heard many years ago that it was a BP that was the basis for the share price action we have seen for years, long before B really started getting researched a few years ago.
It is my contention that they saw first the potential of K due to the p53 activation and later with B due to its wide spectrum possibilities due to being a new arm of medicine
I think they have been intent on either acquiring IPIX for a pittance or put it under. Pure greed and evil.
institutions aren't going to touch it yet (prior to results) and that is what is needed to get the volume to the 50MM+ days I am expecting. Even after great results, only a limited number of funds will touch it IMO until the price starts rising.
I think one of the greatest moves Leo has made was bringing Dr. DeGrado back into the IPIX fold where he should profit handsomely from his creation, Brilacidin.
To have such an esteemed biochemist and well respected expert in his field onboard speaks volumes for IPIX and also showed a major degree of compassion by Leo.
IPIX cred went thru the ceiling when he came onboard.
I think trial results will be very good, but what is going to blow the lid off the medical community IMO is when B in very severe Compassionate Use cases is able to help them as well except for those too far gone (as in lung stem cell damage) in recovering.
That will shock the medical community IMO and will provide a gateway for research by MANY into the other expected areas of worth due to its broad spectrum abilities.
Won't happen overnight, but could happen quite rapidly if B gets the media coverage many of us feel it will garner.
Maybe way off base, but it seems that Brilacidin is a volcano just about to erupt across the world of medicine. I put in these conservative comments to try and not appear as a complete one sided participant in the future of B/IPIX but deep inside I see nothing that can hold either of them back.
I wrote that post in April. How does it stack up against today, 6 months later? BRILACIDIN TODAY LOOKS EVEN STRONGER!!!!
Why?
1. B has been proven in RBL testing to also be effective against unenveloped viruses, thus it should become a target of the DOD as a main drug, if not THE only drug, that could be used to protect troops from all viral and bacterial (remember that to date B has not been tested against any bacteria it could not kill) threats. This is a major funding avenue I expect to come to IPIX after top line results are published.
The above paragraph is a major arm in showing how broad spectrum based is Brilacidin.
2. ALL other Covid vaccines and treatments have shown no ability to aid those patients with anything worse than beginning symptoms of the drugs and must be given very early in the medical cycle to be even somewhat efficient. B will be showing that it can work even on those with much further advanced cases to include very severe symptoms should the Compassionate Use patient stories prove true as to B working on patients 5 to 10 times worse off than those tested in our P2 trial.
3. Broad spectrum -Cannot stress this enough. So far B has shown itself (in RBL testing, not IPIX testing) to be effective or probably effective once RBLs have done further testing against all Covid viruses, many other lines of viruses to include filo viruses (Ebola and Marburg), bacteria, all issues in the GI tract, kidney problems, liver problems, encephalitis, inflammatory lung issues that could include COPD, Asthma, and Bronchitis, and even possibly leaky gut (which leads to leaky brain) and this could result in a possible treatment for ALS (Lou Gehrig's disease), Parkinson's disease, dementia, and even Alzheimer's. Not saying anything finalized yet on the above but testing to date would lead one to believe many of these could come about. Look at the history of B and to date anything thought possible has come to fruition so the future for Brilacidin is so much larger for Brilacidin than simply a Covid treatment is why so many longs are giddy for our future fortunes and for the many sufferers in the world of all these tragic conditions. I have heard it said that to date they have only scratched the surface in regards to the many medical and non-medical uses of Brilacidin. Could one day Brilacidin become a pill, spray, or the like that everybody worldwide would take on a daily or regular basis to protect themselves against a widespread band of dangerous conditions? Sounds far-fetched but so did many of the things we saw in the old time Dick Tracy comic strip and they all have come true. No reason Brilacidin won't become the "penicillin" of the 21st century. Think about it; safe, effective, and not expensive to manufacture. Of course, it would wipe out trillions of dollars per year on worldwide medical costs so one can see why many might not be that happy to see such a wonderful product come to full fruition.
4. Sound too good to be true for a mere penny stock? Will not go into the financial history that has kept IPIX share price at these absurdly low levels, do your own DD and you will find that to this point in time (as a startup biotech) the money just wasn't there to advance Brilacidin and Kevetrin any faster than has been done. But all that stops once we get positive trial results and a number of research grants become available to IPIX.
Right now those finding this stock are the luckiest people alive. You didn't have to endure the hard times, stock price is still low enough for true visionaries to acquire a position that should bring about riches, IPIX/Brilacidin/Kevetrin can no longer be kept hidden no matter how hard BP tries to keep them hidden, and the share price should show some real appreciation by the end of the month or shortly thereafter once trial results are announced.
October is a month for stockholders to sit back and wait as our time finally is at hand to see some returns on our investment.
Even more important, Covid should become a fear of the past for most of the world.
I think there has been nothing but continuing accumulation over the last number of months. That, wash trades, and short term trading made up all the volume but very, very little selling by the longs IMO.
Today's trading doesn't surprise me, or worry me, at all. Simply a sign of desperation IMO.
Not sure about the price prediction. IMO we could see the current trading pattern continue right until trial results are released. Seems like digging your own grave, but then trading reasons on this stock have always been questionable.
If share price continues to hover at this range or even drop a bit, no worries IMO, but I also don't see a massive upside move prior to results.
At least we know it is but a couple of weeks away from finally knowing the end game results.
If nothing else all CU cases should show a massive drop in viral load. No other treatment can do that from what I know.
I would expect that some major media would look awfully sharp if they got a handful of successful CU patients to tell their story about how Brilacidin saved their lives. Would get the word out across the nation as many are currently dying that could be saved IMO.
The academic universities (at least 3 per the PR) IMO are most likely RBLs. If they are doing this much investigation, wouldn't that make it likely the DOD is all over Brilacidin as the top candidate to protect troops from enemy biological threats? I believe the govt is all over B at this point in time.
Compassionate use already has taken place IMO from the tone of the PR in that B was delivered to hospitals and the FDA gave permission to use it to the doctors at these hospitals.
The trial may have taken 29 days but in reality Brilacidin should work within a matter of a handful of days at the MOST. It should immediately destroy the heavy viral load by the 2nd day IMO. So within a week patients that were once iffy as to surviving should be recovering nicely if B works as we expect it has on these patients.
That type of info will be spread quite rapidly thru the COVID treating segment of medicine and the demand for B should become enormous. I also was told IPIX should be able to PR these Compassionate Use success stories.
Makes me wonder if by the time that we get the top line results in mid to late October that we also get a HUGE order from the US government for B to be put in stock. Could be a great Holiday Season for IPIX shareholders.
I now agree with you. But I believe that something was seen by people conducting the trials to make them believe Brilacidin could be a good treatment for patients with more severe cases of Covid that current treatments can't handle.
All in all, extremely positive for me.
Would a person most likely have to take quite a number of hits on the inhaler to get enough Brilacidin to work effectively or should just one or two be good for a day?
Feel I have a basic understanding of what B can do but no clue as to the how it does it as evidenced by the following questions:
1. Can a B molecule kill many virus cells, one after another, or does the B molecule kill just one virus cell and die/become ineffective itself?
2. Does B flood the blood or are there very few B cells compared to a body heavily laden with CV cells? (Is it an Alamo type scene where B is heavily outnumbered or is there a pretty equal amount of B vs CV so that B kills all pretty quickly.
3. Does B clean out the body of virus within the first 3 days of IV and the remaining 2 days were more or less just for cleanup of the body?
4. Would it be safe to say the entire focus of the trial was mainly in the first 5-7 days and after that nothing of importance would occur as all CV virus would be gone and B concentration would also be gone negating any possible safety issues during the balance of the 29 day active trial period and the ensuing 30 days prior to the final check phone call?
5. The main death issue I have heard is if the stem cells in the lungs had already been damaged before B was introduced and thus the patient could not be saved. Would this condition be able to be identified by attending physicians quickly in those not recovering after B treatment?
Any thoughts on the above questions would be appreciated.
With the Compassionate Use statement put out today in the PR, it appears IMO that the results of the trial must have been good. Why else would the FDA allow B to be granted use for Compassionate Use if they hadn't found it to be a useful treatment in the trial?
Now the delay in top line results can be somewhat explained in that if we read it right that this PR shows B must have had very good results for the FDA to allow Compassionate Use (and note B has ALREADY been supplied to specific hospitals).
I predict results were extremely good and the results are being gone over with a fine toothed comb to ensure nothing is wrong with the excellent results they will be revealing in Oct some time.
Connecting the dots makes this a blowout PR!!!!!!
You're thinking again in the same vein as big medicine.
All that was left after the last of June was one follow-up phone call 30 days later to the last patient in the trial. This was a simple question - any problems regarding Covid over the last month? Didn't really provide any other secondary objectives data so quite a minor point regarding the trial.
Data (all data regarding primary and secondary objectives) could have been started to be validated 30 June so by 30-31 July most of the data was looked at or at least a very good part of it.
You are back to everyone sitting on their asses for 30 days (until end of July) in regards to data for that one friggen' phone call to come in.
You would think people running the trial could walk and chew gum at the same time but it seems that may be beyond them.
I have been very vocal regarding what I deem an extremely inefficient method of establishing, running, and reporting results of clinical trials. This is not just for our current trial but all trials and here is my reasoning:
In college golf tournaments today, scorers are placed after every 3 holes. The players must give their scores on the last 3 holes played to them after holes 3,6,9.12,and 15. The scorers then forward this information to the tournament scoring HQ so coaches can be informed on a near real time basis how their team is doing and where they should send some asst. coach out to help a player doing poorly.
I don't see anything like this updating of clinical trial results being done in medicine today. I get the impression that the individual sites only send up their data after all patients are finished. I may be in error on this point but it certainly doesn't seem that raw data from the initial stages from the first patients is forwarded up the line so the CRO big boys can keep an eye on the proceedings and make adjustments to speed up the trial or keep data from being questionable or incorrect. If this had been done for the first 25% of the patients in our trial, it wouldn't have taken an additional 2-3 weeks to approve increasing the dosing from 3 to 5 days. At 25% (30 patients) that means only 15 patients had been given Brilacidin and the CRO/trial overseers who made the decision should have been able to make the decision in a matter of hours once the last patient came in, not the 2-3 weeks that were actually needed. Now expand this to the entire trial and the last patient was done (except for the 30 day later phone call) by the end of June since the 30 day calls were done by the end of July. So IMO the CRO should have had the entire operational data in hand by the end of June and could/should have started validating the data then. But from what I interpret from the 12 Aug PR the validation of the data didn't start until the beginning of Aug.
Who the hell in industry works that way? Things get done ASAP, but I guess medicine is above this or at least a "need for speed" is the last thing on their minds, even in a pandemic.
Don't take this as a knock on our trial - I have been super pissed about Faucci and his shenanigans from the start, the CDC, the approval of all the vaccines with next to no real data establishing their safety (hell of a lot of medical personnel not vaccinated yet so that tells me something is amiss), the total waste of money on trying to "repurpose" old POS drugs to add revs to BPs bottom lines, and much more regarding the pandemic. This clinical trial flow of data in my mind resembles the LA freeways at rush hour - giant periods of simply standing still with nothing accomplished. The running of the trial is just one in a long list of items I find irritating regarding the running of solving the pandemic.
I would have assumed with clinical trials being a large revenue source for Russia and MANY, MANY trials already having been run there that the computer software, language barriers, etc should have been taken care of before the trial started. Am I to think this is the first rodeo for the whole operation and everyone in it?
I just don't buy the BS time wasted. IMO there is a very fine line between getting the data right and just outright inefficiency in getting the job done.
So to me since June 30 it has been 84 days. For 120 patients I would have thought that was enough time to sort the data out.
We will get thru this, Brilacidin will show its true colors, but the massive bureaucracy will continue on for likely decades to come. At this point in time, we will get the info when we get the info. I am good with that but while we wait people are still dying and that seems to matter little anymore, if it ever did to some in power.
Can't go along with that.
I never met Secretariat, but his record stands for itself. His accomplishments were well known and his times for all 3 of the Triple Crown races still stand as the fastest ever run for each race. That tells me all I need to know.
Dr. DeGrado's work, his lab success at UCSF over the last decade or so, his hundreds of publications and vast number of medical awards pretty much do for me what Secretariat's record did - they showed a truly exceptional being in his field.
Now don't compare Brilacidin to any other drug from the turn of the century as none other used a super computer for thousands of hours to fine tune the formulation to maximize benefits and minimize side effects, both of which have been proven time and again in all lab investigations and clinical trials.
Trying to throw shade on Dr. DeGrado's credentials will never fly.
Not correct as to date; PR came out 12 Aug but in it the following was stated:
"Full enrollment in the 120-patient clinical trial was completed in early June 2021. The last patient follow-up visit occurred on July 30, 2021. The subject database remains blinded with the current emphasis on confirmation of all data entered at study sites, as well as completion of source data verification and the necessary checks and reviews by the data management vendor in preparation of database lock."
Rational thoughts always shuts me up. Thanks.
When it takes this long to validate data, my thought is that the trial sites and those running them were pretty weak or the protocol was garbage in not making data points easy to identify and categorize.
For what a company pays for these trials, one would expect they get the right data out of the box and a 2+ month review of the data would not be needed.
I am not overly anxious as to when we actually get the data lock, I am just making observations on the apparent lack of expertise from those conducting the trials to get it right the first time.
I guess one side will say it shows the utmost attention to detail from the medical community, IMO it is more the sign of a general "clusterf***".
A surgeon doesn't leave a patient with an open wound for extra hours so he can go back and examine each knot he tied during the operation. He knows he did it right the first time thru.
Surprised by your "cautiously optimistic" statement.
What possible improvement could Brilacidin have had in testing that would have made you more optimistic than "cautiously"?
Great tests for B and known ineffectiveness of SOC. Seems the scales are pretty tilted IMO.
If everybody knew this why would they be invested in IPIX?
Why are you invested here if other wonder drugs already working?
Why haven't these wonder drugs been made known in USA, the largest market for such drugs?
Your post seems incorrect on so many levels.
Too many people still dying from Covid for there to be something available that could stop it cold once a person has a mild or worse case of it.
This will end my discussion of this topic - FUD IMO.
If trial wasn't large enough to give an EUA, then why did FDA approve it? What one would be saying is that we wasted over 7 months on a too small trial so that we have to do another trial (another 7 months or most likely a much longer time due to larger number of patients) which is ludicrous when talking about a pandemic and they are seeing a treatment that looks like it could solve the whole problem. Actually it is a possibility in the ol' pay-for-play game we are seeing in doing everything to throw revenues at BP vaccines which are spotty at best and possibly lethal at worst.
If FDA puts up such a roadblock (another larger trial) I would bet that the EU, Russia, India, or possibly Japan would authorize the use of B in the meantime and then the FDA would have to explain to the public why other countries have a drug from the USA that isn't allowed to be used by US citizens.
If that turns out to be the case, then IMO some members of the FDA should be tried for murder in that many thousands of patients will have died needlessly in the time it takes to run the larger trial.
I don't see how the SOC could work against Brilacidin in the trial. B attracts the virus and kills it, it should not attract the SOC IMO so the SOC becomes a sideline body, not an active body in the trial, at least in relation to Brilacidin molecules.
We know Rems.... didn't work against B in the in vitro investigation but seemed to have some synergy effect with it.
Expect the same for fav.... but that is only an opinion.
If it is an enveloped virus, then Brilacidin should be very effective against it as B destroys all enveloped viruses.
For all the nervous nellies scared to death about the trial results:
There are only 2 questions that have to be answered by the trial
1 - Can Brilacidin effectively kill the CV19 virus and bring those infected with it back to a state of good health?
Answer: It has proven itself HIGHLY effective at doing this in all in vitro testing and with an SI of 426 the odds are near 100% that it will also effectively kill the CV19 virus in vivo (on actual patients). Remember, science works ALL the time in the same way. No reason to believe in this trial it will work any different.
2 - Is Brilacidin safe in the dosage being given and for the number of dosings being given?
Answer: Again, nearly 100% sure to work safely as dosing strength has proven to have no ill effects in prior trials and the oversight committee allowed the dosings to be increased from 3 to 5 after 25% of patients had completed the trial, thus showing they had no adverse effects up to that point and we heard of no shutdown after the increased dosings that would make us believe there were any problems after the increased number of dosings.
Trial results - Due out any day now. All attempts to try and cast a doubt on them are purely straw men being thrown up by those who are going to be in deep, deep trouble when good results are announced. Know what you own, believe in the science.
My response is they are not working on a cure for a pandemic. I would think that would justify a much faster response, especially when our objectives were pretty self-explanatory and easy to decipher.
Example: Days to recovery/ability to leave hospital and rankings on an ordinal scale that should have been quite easy to identify per the protocol design.
I am beginning to think the CRO and related agencies are being paid by the hour at the speed which they are validating the data.
Being deliberate is one thing, getting the job done with all possible speed to help end a pandemic another. I can't see anybody breaking their ass to get this job done as opposed to it being just another possible drug for some minor condition.
Terrible world when all the powers to be across all areas of society are suspect in their intentions (at least that is how I look at them today).
Problem is if anybody ponies up the $12-16MM to get the prototype completed and move the company from square one, they will also probably want about 90% of the company in return so we current stockholders are left with very little.
Company has let go some very, very important people that leaves the future highly in doubt IMO.
Hoping for the best but unless we see a white knight (which is always more a wish than a fact) we aren't in too good a situation IMO.
The worst thing of all is that the technology, especially now that they would be converting the stranded gas to chemicals, screams as a major win for somebody and in the world of energy $16MM is peanuts. Can't believe some big boy in the energy field (either a company or a wealthy land owner reaping large royalties) hasn't had the guts to give it a go.
Guess the days of the true "wildcat" are over in the energy game.
The science points to Brilacidin being a BIG winner.
Many have doubts, but the science has been consistent thru the life of Brilacidin investigations and trials.
If Brilacidin fails to work, I think mankind is in for a tough road ahead as what new arm of medicine could then work? Brilacidin has yet to find any virus or bacteria it couldn't kill. And to think it does this safely.
Right now the world is looking for any bullet to help them in the fight against viruses. Brilacidin appears to be a nuclear bomb. It will do wonders even if it only does a fraction of what it appears it will be able to accomplish, but I think it will be proven to be the whole package, the golden bullet medicine is looking for.
Just my WAG - no medical training to back it up.
Yup, blame Leo, as though he doesn't have a muzzle on him now to make sure the trial is not tainted in any way with early release of info. He might have info re: data lock but certainly not results.
Irrational statement to blame him for current quiet period.
Who do you feel can hold the FDA accountable? Two top FDA employees quit last week due to White House overriding the FDA authority and that is about as accountable as it can get. Stockholders and individual companies certainly can't make a dent in the armor of the FDA. Again irrational statement.
SI 426, great safety profile, drug actually kills the virus so no way it will cease to work just in this trial so "if this hits" is irrational as well, it should state "when this hits" as the magnitude of this science cannot and will not be held back.
LOL - was you moniker supposed to be "patience" people?
Oxymoron: Dream Big - $11.82/share
Some posts try to denigrate the science of Brilacidin, the foundational drug in a new arm of science created by biochemist Dr. William DeGrado, PhD so for all new eyes to this board here is a quick synopsis to show the level of respect the medical and research communities hold for this science and its creator:
Dr. DeGrado created Brilacidin while working at Polymedix along with the U of Pennsylvania at the beginning of this century. Brilacidin was put thru tens of thousands of hours on the super computer in Pittsburgh, named Big Ben, to analyze varying factors to maximize its benefits and minimize its side effects. One could say Brilacidin was among the first of drugs to be developed using artificial intelligence, or something close to it via high speed analytical computations. Makes it understandable why Brilacidin has never failed a clinical trial to date nor has it failed to kill every bacteria and virus upon which it has been tested with nary an adverse event causing a patient harm!!
When Polymedix went belly up and Cellceutix (later to change its name to Innovation Pharmaceuticals) bought the rights to Brilacidin, Dr. DeGrado opened a lab bearing his name at the University of San Francisco, strictly a medical research facility having only graduate students enrolled. You can find the website for the lab at the following link -- https://pharm.ucsf.edu/degrado
If you go to the right side of the page and read the 'About' section you will find this statement:
------------------------------------------------------------------
In the UC San Francisco lab of William DeGrado, PhD, we study the structural characterization of membrane proteins and de novo protein design in order to understand biological processes relevant to human disease and to develop novel therapeutics.
One primary research interest is de novo design, in which one designs proteins beginning from first principles. This approach critically tests our understanding of protein folding and function, while also laying the groundwork for the design of proteins and biomimetic polymers with properties not seen in nature.
De novo design of proteins has proven to be a useful approach for understanding the features in a protein sequence that cause it to fold into its unique three-dimensional structure. It has been possible to design functionally interesting proteins that bind redox-active cofactors, DNA, and transition metals. This approach has been extended to the design of membrane-active proteins, including ion channels, antibiotics, and fusogenic agents.
We also study the structures and functions of a number of pharmacologically interesting systems, including:
Structure of the M2 proton channel from the influenza A virus
Signal transduction of integrins
Small molecule inhibitors of integrins
Antimicrobial host-defense protein mimics, which show considerable promise for treating antibiotic-resistant infections
Molecules that target protein structures critical to the pathogenesis of HIV and Alzheimer’s disease
----------------------------------------------------
For years this lab has been pumping out into research and medical facilities across the globe well-placed graduates that recognize the capabilities of this new arm of medicine.
Dr. DeGrado himself is a world-recognized leader in his field and has published hundreds of articles, UCSF is a recognized pinnacle in medical research centers, and Brilacidin is maybe the only drug that encompasses so many anti-XXX (viral, bacterial, fungal, inflammatory, etc)capabilities and it does all this with a remarkable safety profile.
This is no scam and is indeed a drug that some have described as "the penicillin of the 21st century". Know what you own as the value of this drug is incredible.